2025 Webinar Series: From Tissue Banking to Advanced Therapies: Regulatory Pathways and Strategic Transitions in Tissue Engineering (Group)

Includes a Live Web Event on 09/03/2025 at 2:00 PM (EDT)

Description: This webinar will explore the rapidly evolving field of Advanced Therapy Medicinal Products (ATMPs) and highlight the strategic opportunity they present for tissue banks—particularly through tissue engineering. Participants will gain a foundational understanding of the historical and regulatory landscape of ATMPs.

While ATMPs are often associated with cell and gene therapies led by blood banks or academic institutions, this session challenges that assumption. It emphasizes how tissue banks are already well-positioned to enter this space, given their existing strengths in donor screening, traceability, sterility, and access to human tissues suitable for scaffolds or regenerative cells.

The session will introduce a gradual, practical approach to transitioning toward GMP-compliant manufacturing, building on current infrastructure and expertise. Attendees will learn how tissue banks can play a key role in advancing clinical applications, driving innovation, and shaping the future of regenerative medicine.

Target Audience: This session is ideal for professionals in tissue banking who are involved in or interested in innovation, regulatory strategy, and clinical advancement.

Juan Pablo Aguilar Alemán, PhD

National Academic Director of Biomedical Engineering

Tecnológico de Monterrey

Juan Pablo holds a PhD in Biomedicine and Tissue Engineering and an MSc inBiomedical Engineering from the University of Barcelona, along with a BSc inBiomedical Engineering from Tecnológico de Monterrey. He is a Level I member ofMexico’s National System of Researchers (SNI-I) and a current member of the Scientificand Technical Affairs Committee (STAC) of the AmericanAssociation of Tissue Banks (AATB).

He brings over 15 years of international experience in translationalresearch, biomedical innovation, and regulatory science. He has led thedevelopment and scale-up of collagen-based medical devices, includingdecellularized tissues, heart valves, dermis, and peripheral nerves, securingregulatory approvals and national patents. His expertise spans the full productlifecycle under GMP and ISO 13485 standards, with a strong focus onquality-by-design and risk-based methodologies.

Currently, he leads the scientific pipeline at ITC(Instituto de Terapia Celular), driving the development of AdvancedTherapy Medicinal Products (ATMPs) based on mesenchymal stromalcells (MSCs), extracellular vesicles (EVs), and biofunctional scaffolds. Inparallel, he serves as National Academic Director of BiomedicalEngineering at Tecnológico de Monterrey, fosteringinnovation-driven education and strategic collaboration between academia,industry, and clinical stakeholders.